Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Author(s): Nicholas Manolios* and Guojiang Hou

DOI: 10.2174/1871523022666230201144553

DownloadDownload PDF Flyer Cite As
Anti-inflammatory Effects of First-line Anti-arthritic Drugs on T-cell Activation

Page: [188 - 193] Pages: 6

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Aim: The in vitro effects of commonly used first-line anti-arthritic drugs on early stages of T-cell activation were examined.

Methods: The 2B4.11 murine T cell hybridoma cell line recognizing pigeon cytochrome c (PCC) as the antigen was co-cultured with the histocompatible antigen presenting B cell hybridoma line LK35.2, PCC, and anti-arthritic drugs, including methotrexate, hydroxychloroquine, salazopyrine, cyclosporin, and leflunomide. After 16 hours of incubation, the supernatant was removed, and cytokines were assayed.

Results: Anti-arthritic drugs inhibited the production of pro-inflammatory cytokines IL-2, IL-6, IFN-γ, GM-CSF, and TNF-α (Th1 cytokines) to a varying extent. Surprisingly, leflunomide, salazopyrine, prednisone and indomethacin as well as blocking Th1 cytokines, stimulated the production of the anti-inflammatory cytokine IL-10, a Th2 cytokine.

Conclusion: Anti-arthritic medications can inhibit the production of pro-inflammatory cytokines and in some cases, incite a Th2 response that could potentially inhibit the progression of the immune response.

Graphical Abstract

[1]
Schulze-Koops, H.; Kalden, J.R. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2001, 15(5), 677-691.
[http://dx.doi.org/10.1053/berh.2001.0187] [PMID: 11812015]
[2]
Cheung, T.T.; McInnes, I.B. Future therapeutic targets in rheumatoid arthritis? Semin. Immunopathol., 2017, 39(4), 487-500.
[http://dx.doi.org/10.1007/s00281-017-0623-3] [PMID: 28451787]
[3]
Venkatesha, S.; Dudics, S.; Acharya, B.; Moudgil, K. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int. J. Mol. Sci., 2014, 16(1), 887-906.
[http://dx.doi.org/10.3390/ijms16010887] [PMID: 25561237]
[4]
White, D.; Chapman, P.; Ching, D. Retention on methotrexate: The rheumatology audit partnership New Zealand experience. Intern. Med. J., 2017, 47, 34.
[5]
O’Dell, J.R.; Mikuls, T.R.; Taylor, T.H.; Ahluwalia, V.; Brophy, M.; Warren, S.R.; Lew, R.A.; Cannella, A.C.; Kunkel, G.; Phibbs, C.S.; Anis, A.H.; Leatherman, S.; Keystone, E. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med., 2013, 369(4), 307-318.
[http://dx.doi.org/10.1056/NEJMoa1303006] [PMID: 23755969]
[6]
Tett, S.; Day, R.; Cutler, D. Hydroxychloroquine relative bioavailability: Within subject reproducibility. Br. J. Clin. Pharmacol., 1996, 41(3), 244-246.
[http://dx.doi.org/10.1111/j.1365-2125.1996.tb00190.x] [PMID: 8866926]
[7]
Park, J.Y.; Kim, K.A.; Lee, Y.H.; Park, S.W.; Lee, G.H.; Ryu, J.H. Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: A single dose, randomized, open-label, two-way crossover study. Int. J. Clin. Pharmacol. Ther., 2010, 48(4), 291-295.
[http://dx.doi.org/10.5414/CPP48291] [PMID: 20353751]
[8]
Tokui, K.; Asai, Y.; Arakawa, T.; Matsumoto, T.; Nabeshima, T. Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers. Biol. Pharm. Bull., 2002, 25(2), 264-267.
[http://dx.doi.org/10.1248/bpb.25.264] [PMID: 11853180]
[9]
Lucas, S. The pharmacology of indomethacin. Headache, 2016, 56(2), 436-446.
[http://dx.doi.org/10.1111/head.12769] [PMID: 26865183]
[10]
Ji, P.; Doddapaneni, S. Prednisone delayed-release tablets.Clinical Pharmacology Review; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000ClinPharmR.pdf
[11]
Manolios, N.; Collier, S.; Taylor, J.; Pollard, J.; Harrison, L.C.; Bender, V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat. Med., 1997, 3(1), 84-88.
[http://dx.doi.org/10.1038/nm0197-84] [PMID: 8986747]
[12]
Wahl, C.; Liptay, S.; Adler, G.; Schmid, R.M. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest., 1998, 101(5), 1163-1174.
[http://dx.doi.org/10.1172/JCI992] [PMID: 9486988]
[13]
MacDermott, R.P. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am. J. Gastroenterol., 2000, 95(12), 3343-3345.
[http://dx.doi.org/10.1111/j.1572-0241.2000.03342.x] [PMID: 11151859]
[14]
McBride, R.H. In vitro effect of sulphasalazine and its metabolites on human lymphocyte activation. Master Thesis, Graduate College of Bowling Green State University, USA,, 1994, 1-43.
[15]
Paccani, S.R.; Boncristiano, M.; Ulivieri, C.; D’Elios, M.M.; Del Prete, G.; Baldari, C.T. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J. Biol. Chem., 2002, 277(2), 1509-1513.
[http://dx.doi.org/10.1074/jbc.M110676200] [PMID: 11700329]
[16]
Palay, D.A.; Cluff, C.W.; Wentworth, P.A.; Ziegler, H.K. Cyclosporine inhibits macrophage-mediated antigen presentation. J. Immunol., 1986, 136(12), 4348-4353.
[http://dx.doi.org/10.4049/jimmunol.136.12.4348] [PMID: 3486899]
[17]
Breedveld, F.C.; Dayer, J.M. Leflunomide: Mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59(11), 841-849.
[http://dx.doi.org/10.1136/ard.59.11.841] [PMID: 11053058]
[18]
Smolen, J.S.; Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov., 2003, 2(6), 473-488.
[http://dx.doi.org/10.1038/nrd1109] [PMID: 12776222]
[19]
Xu, X.; Williams, J.W.; Bremer, E.G.; Finnegan, A.; Chong, A.S.F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem., 1995, 270(21), 12398-12403.
[http://dx.doi.org/10.1074/jbc.270.21.12398] [PMID: 7759480]
[20]
Elder, R.T.; Xu, X.; Williams, J.W.; Gong, H.; Finnegan, A.; Chong, A.S. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol., 1997, 159(1), 22-27.
[http://dx.doi.org/10.4049/jimmunol.159.1.22] [PMID: 9200434]
[21]
Zeyda, M.; Poglitsch, M.; Geyeregger, R.; Smolen, J.S.; Zlabinger, G.J.; Hörl, W.H.; Waldhäusl, W.; Stulnig, T.M.; Säemann, M.D. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum., 2005, 52(9), 2730-2739.
[http://dx.doi.org/10.1002/art.21255] [PMID: 16142756]
[22]
Schmidt, A.; Schwind, B.; Gillich, M.; Brune, K.; Hinz, B. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography. Biomed. Chromatogr., 2003, 17(4), 276-281.
[http://dx.doi.org/10.1002/bmc.244] [PMID: 12833393]
[23]
Dimitrova, P.; Skapenko, A.; Herrmann, M.L.; Schleyerbach, R.; Kalden, J.R.; Schulze-Koops, H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J. Immunol., 2002, 169(6), 3392-3399.
[http://dx.doi.org/10.4049/jimmunol.169.6.3392] [PMID: 12218161]
[24]
Burger, D.; Begué-Pastor, N.; Benavent, S.; Gruaz, L.; Kaufmann, M.T.; Chicheportiche, R.; Dayer, J.M. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Br. J. Rheumatol., 2003, 42(1), 89-96.
[http://dx.doi.org/10.1093/rheumatology/keg038] [PMID: 12509619]
[25]
Mauri, C.; Feldmann, M.; Williams, R.O. Down-regulation of Th1-mediated pathology in experimental arthritis by stimulation of the Th2 arm of the immune response. Arthritis Rheum., 2003, 48(3), 839-845.
[http://dx.doi.org/10.1002/art.10832] [PMID: 12632440]
[26]
Constantin, A.; Loubet-Lescoulié, P.; Lambert, N.; Yassine-Diab, B.; Abbal, M.; Mazières, B.; de Préval, C.; Cantagrel, A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum., 1998, 41(1), 48-57.
[http://dx.doi.org/10.1002/1529-0131(199801)41:1<48:AID-ART7>3.0.CO;2-K] [PMID: 9433869]